惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

量子位
博客园_首页
Google DeepMind News
Google DeepMind News
博客园 - Franky
The GitHub Blog
The GitHub Blog
GbyAI
GbyAI
有赞技术团队
有赞技术团队
Microsoft Azure Blog
Microsoft Azure Blog
G
Google Developers Blog
Recent Announcements
Recent Announcements
A
About on SuperTechFans
博客园 - 【当耐特】
博客园 - 三生石上(FineUI控件)
酷 壳 – CoolShell
酷 壳 – CoolShell
美团技术团队
罗磊的独立博客
IT之家
IT之家
博客园 - 聂微东
Stack Overflow Blog
Stack Overflow Blog
Jina AI
Jina AI
腾讯CDC
P
Proofpoint News Feed
Hugging Face - Blog
Hugging Face - Blog
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Becton, Dickinson: Value Or Overvalued Even Now?
2026-04-20 · via All Articles on Seeking Alpha

Summary

  • Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach.
  • Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation.
  • I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at current prices.
  • BDX fulfills key quality and safety criteria, though the spin-off reduces diversification and margin potential, warranting a conservative 15x P/E multiple.
  • I do much more than just articles at Wolf of Value: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
BD Canada"s head office building in Mississauga, On, Canada.

JHVEPhoto/iStock Editorial via Getty Images

I cover quite a few healthcare and healthtech/medtech companies. I like investing in the cheap, qualitative ones that have an appealing market share and a solid moat. Becton, Dickinson (BDX) may be such

35.16K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment. Short-term trading, options trading/investment and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved. I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about. Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.